Allergy medications and dementia risk is a topic of growing concern, particularly for older adults who rely on antihistamines to manage hay fever, urticaria, or other allergic conditions. Certain allergy medicines — specifically older, first-generation antihistamines such as chlorphenamine and promethazine — belong to a class of drugs called anticholinergics, which have been associated in observational research with an increased risk of dementia. This article explains which allergy medications are implicated, what the current evidence shows, and what UK guidance recommends to help patients manage allergies safely.
Summary: Certain allergy medications — particularly first-generation anticholinergic antihistamines such as chlorphenamine — have been associated with increased dementia risk in observational studies, though no confirmed causal link has been established.
- First-generation antihistamines (e.g., chlorphenamine, promethazine) are anticholinergic drugs that block acetylcholine, a neurotransmitter critical for memory and learning.
- Second-generation antihistamines (cetirizine, loratadine, fexofenadine) have a much lower anticholinergic burden and are recommended as first-line allergy treatment in UK guidance (NICE CKS).
- A 2015 JAMA Internal Medicine study found cumulative anticholinergic exposure equivalent to three or more years of daily use was associated with a 54% higher dementia risk in older adults.
- Anticholinergic burden — the cumulative effect of multiple anticholinergic medicines — is assessed using validated tools such as the ACB scale and is a key focus of NHS structured medication reviews.
- NICE medicines optimisation guidance (NG5) and NHS England's structured medication review programme encourage reducing unnecessary anticholinergic prescribing, especially in adults aged over 65.
- Intranasal corticosteroids (e.g., beclometasone, fluticasone) are effective, anticholinergic-free alternatives for allergic rhinitis, often preferred for persistent or moderate-to-severe symptoms.
Table of Contents
- Which allergy medications have been linked to dementia risk?
- Understanding the anticholinergic effect on the brain
- What the current evidence says about long-term use
- UK guidance on safer allergy treatment options
- When to speak to your GP about your allergy medication
- Reducing risk: alternatives and practical steps for patients
- Frequently Asked Questions
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Which allergy medications have been linked to dementia risk?
First-generation antihistamines such as chlorphenamine and promethazine carry the greatest concern due to their anticholinergic properties; second-generation antihistamines (cetirizine, loratadine, fexofenadine) have a much lower anticholinergic burden and are considered safer.
The allergy medications most commonly discussed in relation to dementia risk are the older, first-generation antihistamines. These include well-known over-the-counter medicines such as chlorphenamine and promethazine. These drugs belong to a broader class of medicines known as anticholinergics — substances that block the neurotransmitter acetylcholine in the nervous system.
Diphenhydramine is another first-generation antihistamine with anticholinergic properties; however, in the UK it is primarily licensed and marketed for the short-term relief of temporary sleep disturbance rather than as a routine allergy treatment, and it is not considered a standard first-line option for allergic conditions.
It is important to note that not all allergy medications carry the same level of concern. Newer, second-generation antihistamines — including cetirizine, loratadine, and fexofenadine — are considered 'non-sedating' and have a much lower anticholinergic burden. These are generally regarded as safer for long-term use, particularly in older adults.
The concern around first-generation antihistamines and dementia is not new. A widely cited 2015 study published in JAMA Internal Medicine (Gray et al.) found an association between cumulative use of anticholinergic medicines and an increased risk of dementia. However, it is essential to understand that association does not confirm causation, and the research landscape continues to evolve. UK prescribing policy — including NICE medicines optimisation guidance (NG5) and NHS England's structured medication review programme — encourages prescribers and patients to consider the cumulative anticholinergic load of their medicines, particularly in older populations.
| Antihistamine Generation | Examples | Anticholinergic Burden | CNS Penetration | Dementia Concern | UK First-Line Status | Key Cautions |
|---|---|---|---|---|---|---|
| First-generation (sedating) | Chlorphenamine, promethazine, diphenhydramine | High | Readily crosses blood-brain barrier | Associated with increased dementia risk; 54% higher risk with ≥3 years cumulative use (Gray et al., 2015) | Not recommended as first-line; avoid long-term use in older adults | Drowsiness, confusion, falls risk, urinary retention, narrow-angle glaucoma; impairs driving |
| Second-generation (non-sedating) | Cetirizine, loratadine, fexofenadine | Low | Minimal CNS penetration | No significant association identified; considered safer for long-term use | NICE CKS and BSACI recommended first-line for allergic rhinitis and urticaria | Generally well tolerated; cetirizine may cause mild drowsiness in some individuals |
| Intranasal corticosteroids | Beclometasone, fluticasone nasal sprays | None | Negligible systemic absorption | No anticholinergic risk; no dementia association | Preferred over antihistamines for persistent or moderate-to-severe allergic rhinitis (NICE CKS; ARIA) | Requires consistent daily use; takes several days for full effect; correct technique essential |
| Allergen immunotherapy | NHS specialist desensitisation programmes | None | Not applicable | No dementia association; reduces need for ongoing medication | Specialist-initiated for selected patients via NHS allergy services | Eligibility determined by specialist; not suitable for all patients |
Understanding the anticholinergic effect on the brain
Anticholinergic drugs block acetylcholine receptors in the brain, reducing activity of a neurotransmitter essential for memory and learning — a mechanism also implicated in Alzheimer's disease. First-generation antihistamines cross the blood-brain barrier, compounding cognitive risk.
To understand why certain allergy medications may be linked to cognitive concerns, it helps to understand how anticholinergic drugs work. Acetylcholine is a key neurotransmitter involved in memory, learning, and attention. Anticholinergic medicines block muscarinic receptors throughout the body and brain, reducing acetylcholine activity. In the short term, this can cause side effects such as:
Experiencing these side effects? Our pharmacists can help you navigate them →
-
Drowsiness and sedation
-
Confusion or 'brain fog'
-
Dry mouth and blurred vision
-
Urinary retention
-
Constipation
Important UK safety cautions: sedating antihistamines can impair your ability to drive or operate machinery — do not do so if you feel drowsy. Older adults are at increased risk of falls. These medicines should be used with particular caution in people with prostatic hypertrophy (enlarged prostate) due to the risk of urinary retention, and in those with narrow-angle glaucoma. If you experience sudden eye pain or a rapid change in vision, seek urgent medical attention, as this may indicate acute angle-closure glaucoma.
In the brain specifically, reduced cholinergic activity is also a hallmark feature of Alzheimer's disease, which is why researchers have been interested in whether long-term anticholinergic exposure might accelerate or contribute to neurodegeneration.
First-generation antihistamines readily cross the blood-brain barrier, meaning they exert direct effects on the central nervous system. This is why they cause sedation — and why they are of greater concern from a cognitive standpoint than second-generation antihistamines, which have much lower CNS penetration. The concept of 'anticholinergic burden' refers to the cumulative effect of taking multiple medicines with anticholinergic properties simultaneously, which can compound cognitive risk, particularly in older adults whose brains may already have reduced cholinergic reserve. Healthcare professionals use tools such as the Anticholinergic Cognitive Burden (ACB) scale — one of several validated tools, including the Anticholinergic Risk Scale (ARS) — to help assess this risk in individual patients, alongside clinical judgement.
What the current evidence says about long-term use
Observational studies suggest an association between cumulative anticholinergic antihistamine use and increased dementia risk, but no causal link has been confirmed and important confounding factors limit current evidence.
The evidence linking long-term anticholinergic antihistamine use to dementia risk is suggestive but not conclusive. Several large observational studies have found statistically significant associations between cumulative anticholinergic exposure and increased dementia incidence.
The 2015 JAMA Internal Medicine study (Gray et al.), which analysed data from over 3,400 older adults, found that those with cumulative anticholinergic exposure equivalent to daily use for three or more years had a 54% higher risk of dementia compared with non-users. This risk estimate applied across a range of anticholinergic drug classes and was based on cumulative standardised daily dose rather than a simple duration threshold for any single medicine.
A 2019 study in the BMJ (Coupland et al.), using UK Clinical Practice Research Datalink (CPRD) data, similarly found associations between anticholinergic prescribing and dementia risk. Importantly, the strongest associations in that study were observed for certain anticholinergic classes — particularly tricyclic antidepressants and bladder antimuscarinics — whilst findings for antihistamines were weaker and less consistent. This nuance is important: the evidence does not implicate all anticholinergic medicines equally.
These studies have important limitations. Observational research cannot fully account for confounding factors — for example, people who take sedating antihistamines long-term may have underlying conditions that independently increase dementia risk. Additionally, some researchers have raised the possibility of 'reverse causation', whereby early, undiagnosed dementia leads to increased use of certain medications rather than the other way around.
At present, there is no definitive proof that taking first-generation antihistamines causes dementia, and there is no current class-wide warning from UK or European regulatory agencies confirming a causal link. Nevertheless, the precautionary principle applies — particularly for older adults, those with existing cognitive concerns, or individuals taking multiple anticholinergic medicines. The scientific consensus is that unnecessary long-term use of high-burden anticholinergic drugs should be avoided where safer alternatives exist.
UK guidance on safer allergy treatment options
NICE CKS recommends second-generation antihistamines (cetirizine, loratadine, fexofenadine) as first-line allergy treatment, with intranasal corticosteroids preferred for persistent allergic rhinitis — both options carry no significant anticholinergic risk.
UK clinical guidance supports a cautious approach to anticholinergic medicines, particularly in older adults. NICE Clinical Knowledge Summaries (CKS) for allergic rhinitis (hay fever) recommend second-generation, non-sedating antihistamines as the first-line pharmacological treatment for most patients. These include:
-
Cetirizine (10 mg once daily in adults)
-
Loratadine (10 mg once daily in adults)
-
Fexofenadine (120 mg once daily for seasonal allergic rhinitis in adults)
Doses are for adults and may differ in children or in those with renal impairment; always refer to the BNF or the medicine's Summary of Product Characteristics (SmPC) for full dosing guidance. These agents have a significantly lower anticholinergic burden and do not readily cross the blood-brain barrier, making them considerably safer for long-term use.
NICE CKS and specialist guidance from the British Society for Allergy and Clinical Immunology (BSACI), supported by the ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines, also recommend intranasal corticosteroids (such as beclometasone or fluticasone nasal sprays) as highly effective options for allergic rhinitis, often preferred over antihistamines for persistent or moderate-to-severe symptoms. These carry no anticholinergic risk and many are now available without prescription.
NICE medicines optimisation guidance (NG5) and NHS England's structured medication review (SMR) programme provide frameworks for reviewing patients' overall anticholinergic burden, particularly in those aged over 65 or taking multiple medicines. If you are currently taking a first-generation antihistamine such as chlorphenamine on a regular basis, it is worth discussing with your GP or pharmacist whether a switch to a second-generation alternative would be appropriate for your circumstances.
If you experience any suspected side effects from your allergy medication, you can report these to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.
When to speak to your GP about your allergy medication
Speak to your GP if you are aged 65 or over, take multiple anticholinergic medicines, have noticed memory changes, or have used first-generation antihistamines daily for more than a few weeks without a formal review.
Most people who take antihistamines occasionally — for example, during hay fever season or for an acute allergic reaction — are unlikely to face significant long-term cognitive risk. However, there are specific situations where it is advisable to speak to your GP or pharmacist about your allergy medication:
-
You are aged 65 or over and regularly take a first-generation antihistamine such as chlorphenamine or promethazine
-
You take multiple medicines with anticholinergic properties (e.g., bladder medications, tricyclic antidepressants, or sleep aids alongside antihistamines)
-
You or a family member have noticed memory problems, confusion, or cognitive changes
-
You have been using antihistamines daily for more than a few weeks without a formal review
-
You have a personal or family history of dementia and are concerned about cumulative risk
Seek urgent medical attention if you or someone you care for experiences any of the following whilst taking a sedating antihistamine: sudden or severe confusion or delirium; inability to pass urine (acute urinary retention); severe constipation with abdominal pain; or sudden eye pain or rapid changes in vision, which may indicate acute angle-closure glaucoma.
Not sure if this is normal? Chat with one of our pharmacists →
Do not drive or operate machinery if you feel drowsy after taking a sedating antihistamine.
Your GP can conduct a medicines review to assess your overall anticholinergic burden and recommend safer alternatives where appropriate. In some cases, referral to a specialist allergy clinic may be warranted if your symptoms are not well controlled on second-generation antihistamines alone. It is important not to stop any prescribed medication abruptly without medical advice, as this could affect the management of your underlying condition. If you are buying antihistamines over the counter, your community pharmacist is also an excellent first point of contact for guidance.
Reducing risk: alternatives and practical steps for patients
Switching to a second-generation antihistamine, using intranasal corticosteroids, requesting a structured medicines review, and exploring allergen immunotherapy are practical steps to manage allergies whilst minimising anticholinergic cognitive risk.
Effective allergy management does not require the use of high-burden anticholinergic medicines. There are several practical steps patients can take to manage their allergies safely whilst minimising any potential cognitive risk.
Switch to a second-generation antihistamine. If you currently use chlorphenamine or another first-generation antihistamine regularly, ask your GP or pharmacist about switching to cetirizine, loratadine, or fexofenadine. These are widely available, often inexpensive, and are recommended as first-line treatment for allergic rhinitis and urticaria in UK guidance (NICE CKS; BSACI guidelines). Efficacy can vary between individuals, so discuss the best option for your circumstances with a healthcare professional.
Consider intranasal corticosteroids. For allergic rhinitis (hay fever), nasal steroid sprays are often more effective than antihistamines for nasal symptoms and carry no anticholinergic risk. Many are now available without prescription. For best results, these sprays need to be used regularly and with correct technique — they do not provide immediate relief and may take several days of consistent use to reach full effect. Your pharmacist or GP can advise on correct administration.
Explore allergen immunotherapy. For carefully selected patients, allergen immunotherapy (desensitisation) — available through NHS specialist allergy services — can provide long-term relief by modifying the immune response to specific allergens, potentially reducing the need for ongoing medication. Eligibility is determined by a specialist following assessment, and NHS availability is subject to local commissioning and relevant NICE Technology Appraisals (for example, for grass pollen and house dust mite sublingual immunotherapy). Not all patients will be suitable.
Request a medicines review. Ask your GP surgery for a structured medication review, particularly if you are older or taking several medicines. This is a routine NHS service, supported by NICE medicines optimisation guidance (NG5) and NHS England's structured medication review programme, and can identify opportunities to reduce your overall anticholinergic burden.
Keep a symptom diary. Tracking when and why you use antihistamines can help identify triggers and inform discussions with your healthcare team about the most appropriate long-term strategy.
Ultimately, the relationship between allergy medications and dementia risk remains an area of active research. Whilst there is no confirmed causal link, adopting a precautionary approach — particularly for older adults — is both reasonable and supported by current UK clinical guidance.
Frequently Asked Questions
Do all allergy medications increase the risk of dementia?
No. Only first-generation antihistamines such as chlorphenamine and promethazine — which have significant anticholinergic properties — have been associated with increased dementia risk in observational studies. Second-generation antihistamines including cetirizine, loratadine, and fexofenadine have a much lower anticholinergic burden and are not considered a significant concern.
Should I stop taking my antihistamine because of the dementia risk?
Do not stop any prescribed medication without first speaking to your GP or pharmacist. For most people who use antihistamines occasionally, the risk is likely to be low; however, if you regularly take a first-generation antihistamine, a medicines review can help identify whether switching to a safer alternative is appropriate for your circumstances.
Which antihistamine is safest for long-term use in older adults?
Second-generation antihistamines — cetirizine, loratadine, and fexofenadine — are recommended as the safest options for long-term use in older adults, as they have a low anticholinergic burden and do not readily cross the blood-brain barrier. NICE CKS recommends these as first-line pharmacological treatment for allergic rhinitis.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
